Accurate Wealth Management LLC Sells 353 Shares of Zoetis Inc. (NYSE:ZTS)

Accurate Wealth Management LLC decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 14.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,037 shares of the company’s stock after selling 353 shares during the quarter. Accurate Wealth Management LLC’s holdings in Zoetis were worth $333,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new stake in shares of Zoetis in the third quarter valued at approximately $31,000. First Personal Financial Services acquired a new position in Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis in the 3rd quarter valued at $33,000. Dunhill Financial LLC grew its position in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Quarry LP increased its holdings in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ZTS shares. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $211.89.

Zoetis Trading Up 1.3 %

Shares of Zoetis stock opened at $169.30 on Friday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The stock has a market capitalization of $76.38 billion, a P/E ratio of 31.82, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. The company has a 50-day simple moving average of $171.25 and a 200 day simple moving average of $180.07. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business posted $1.36 earnings per share. Research analysts expect that Zoetis Inc. will post 5.91 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.18%. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is currently 32.52%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.